D-luciferin(Firefly luciferin)

Molecular Weight (MW)	280.32
Formula	C11H8N2O3S2
CAS No.	2591-17-5
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 56 mg/mL (199.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Other info	Chemical Name: (4S)-2-(6-hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid InChi Key: BJGNCJDXODQBOB-SSDOTTSWSA-N InChi Code: InChI=1S/C11H8N2O3S2/c14-5-1-2-6-8(3-5)18-10(12-6)9-13-7(4-17-9)11(15)16/h1-3,7,14H,4H2,(H,15,16)/t7-/m1/s1 SMILES Code: O=C([C@@H]1N=C(C2=NC3=CC=C(O)C=C3S2)SC1)O
Synonyms	D-(-)-Luciferin; Firefly luciferin

Molecular Weight (MW)

280.32

Formula

C11H8N2O3S2

CAS No.

2591-17-5

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 56 mg/mL (199.8 mM)

Water: <1 mg/mL

Ethanol: <1 mg/mL

Other info

Chemical Name: (4S)-2-(6-hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid

InChi Key: BJGNCJDXODQBOB-SSDOTTSWSA-N

InChi Code: InChI=1S/C11H8N2O3S2/c14-5-1-2-6-8(3-5)18-10(12-6)9-13-7(4-17-9)11(15)16/h1-3,7,14H,4H2,(H,15,16)/t7-/m1/s1

SMILES Code: O=C([C@@H]1N=C(C2=NC3=CC=C(O)C=C3S2)SC1)O

Synonyms

D-(-)-Luciferin; Firefly luciferin

In Vitro	In vitro activity: D-luciferin reacts with luciferase, ATP and oxygen with light emission, and the light is detected by a sensitive photographic film, thereby permitting the visualization of the alkaline phosphatase-conjugated antibodies.
In Vivo	In an immunocompetent mouse model of ovarian cancer, use of D-luciferin substrate and firefly luciferase preserves tumor-host immune interactions, since bioluminescent imaging is a more sensitive indication of tumor growth than weight gain.
Animal model	Mice
Formulation & Dosage	In vivo BLI is performed using a cooled charge-coupled device camera system (IVIS Imaging System 100) 3, 5, 7, 10, 12, 14, 19, 21, 24, and 28 days after the inoculation of HCT116-Luc cells. Mice are injected with 75 mg/kg D-luciferin in 100 μL of phosphate-buffered saline subcutaneously near the scapula and were placed in the light-tight chamber of the imaging system under isoflurane anesthesia. Beginning 5 min after injection, dorsal luminescent images with an exposure time of 1 s are acquired sequentially at a rate of one image per min until 20 min after D-luciferin injection. Data acquisition is continued until 40 min postinjection on days 3 or 5 and until 25 min on day 7, because of the prolonged time course of light emission. Binning is 4 and the field of view is 15 cm.
References	J Clin Chem Clin Biochem. 1987 Aug;25(8):511-4; J Immunother Cancer. 2015 May 19;3:16; Int J Biomed Imaging. 2010;2010:471408.

In Vitro

In vitro activity: D-luciferin reacts with luciferase, ATP and oxygen with light emission, and the light is detected by a sensitive photographic film, thereby permitting the visualization of the alkaline phosphatase-conjugated antibodies.

In Vivo

In an immunocompetent mouse model of ovarian cancer, use of D-luciferin substrate and firefly luciferase preserves tumor-host immune interactions, since bioluminescent imaging is a more sensitive indication of tumor growth than weight gain.

Animal model

Mice

Formulation & Dosage

In vivo BLI is performed using a cooled charge-coupled device camera system (IVIS Imaging System 100) 3, 5, 7, 10, 12, 14, 19, 21, 24, and 28 days after the inoculation of HCT116-Luc cells. Mice are injected with 75 mg/kg D-luciferin in 100 μL of phosphate-buffered saline subcutaneously near the scapula and were placed in the light-tight chamber of the imaging system under isoflurane anesthesia. Beginning 5 min after injection, dorsal luminescent images with an exposure time of 1 s are acquired sequentially at a rate of one image per min until 20 min after D-luciferin injection. Data acquisition is continued until 40 min postinjection on days 3 or 5 and until 25 min on day 7, because of the prolonged time course of light emission. Binning is 4 and the field of view is 15 cm.

References

J Clin Chem Clin Biochem. 1987 Aug;25(8):511-4; J Immunother Cancer. 2015 May 19;3:16; Int J Biomed Imaging. 2010;2010:471408.

CAS NO:	2591-17-5
规格:	≥98%

包装	价格(元)
10mg	询价
25mg	询价
50mg	询价
100mg	询价
250mg	询价
500mg	询价
1g	询价